Shares of Elanco Animal Health Inc (ELAN) surged 9.25% in pre-market trading on Thursday following the release of the company's impressive second-quarter results and an upward revision of its full-year 2025 guidance.

Elanco reported Q2 adjusted earnings of $0.26 per share, surpassing analysts' expectations of $0.20. While this represents a decrease from $0.30 in the same period last year, it demonstrates the company's resilience in a challenging market. Revenue for the quarter ended June 30 reached $1.24 billion, up from $1.18 billion a year earlier and exceeding the FactSet consensus estimate of $1.19 billion.

The animal health company has raised its full-year 2025 outlook, now projecting adjusted earnings per share between $0.85 and $0.91, up from the previous forecast of $0.80 to $0.86. Revenue guidance for 2025 has also been increased to a range of $4.57 billion to $4.62 billion, compared to the earlier projection of $4.51 billion to $4.58 billion. This optimistic outlook, coupled with the strong Q2 performance, has fueled investor enthusiasm, driving the significant pre-market rally.